Literature DB >> 1648861

Ganglioside GD3 shedding by human gliomas.

O Nakamura1, M Iwamori, M Matsutani, K Takakura.   

Abstract

The proportion of ganglioside GD3 increases in glioma tissue and GD3 content is correlated with malignancy of gliomas. This ganglioside can be detected in the sera of patients with glioma by thin-layer chromatographic analysis. Ganglioside GD3 was not detected in the sera of healthy donors and astrocytoma grade 2 patients. However, serum GD3 was detected in one of three astrocytoma grade 3 patients and seven of nine glioblastoma patients. These results show that shedding of GD3 increases in proportion to the degree of malignancy of gliomas. Nevertheless, all of the glioblastoma patients in this study were advanced cases. Considering the high reliability of radiological diagnostic techniques in the neurosurgical field, further study will be necessary to clarify the relationships between the GD3 level in serum and the properties of tumours.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648861     DOI: 10.1007/bf01405694

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  12 in total

1.  Gangliosides and neutral glycosphingolipids in human brain tumors: specificity and their significance.

Authors:  Y Eto; S Shinoda
Journal:  Adv Exp Med Biol       Date:  1982       Impact factor: 2.622

2.  [Lipid composition of human malignant brain tumors].

Authors:  O Nakamura; E Ishihara; M Iwamori; T Nagai; M Matsutani; K Nomura; K Takakura
Journal:  No To Shinkei       Date:  1987-03

3.  Shedding of GD2 ganglioside by human neuroblastoma.

Authors:  S Ladisch; Z L Wu; S Feig; L Ulsh; E Schwartz; G Floutsis; F Wiley; C Lenarsky; R Seeger
Journal:  Int J Cancer       Date:  1987-01-15       Impact factor: 7.396

4.  Gangliosides of human cerebral astrocytomas.

Authors:  T D Traylor; E L Hogan
Journal:  J Neurochem       Date:  1980-01       Impact factor: 5.372

Review 5.  Ganglioside GD3: structure, cellular distribution, and possible function.

Authors:  T N Seyfried; R K Yu
Journal:  Mol Cell Biochem       Date:  1985-09       Impact factor: 3.396

6.  Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

Authors:  W G Dippold; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides.

Authors:  S Ladisch; B Gillard; C Wong; L Ulsh
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

8.  Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas.

Authors:  J Portoukalian; M J David; X Shen; M Richard; C Dubreuil
Journal:  Biochem Int       Date:  1989-04

9.  Ganglioside GD3 shedding by human malignant melanoma cells.

Authors:  H Bernhard; K H Meyer zum Büschenfelde; W G Dippold
Journal:  Int J Cancer       Date:  1989-07-15       Impact factor: 7.396

10.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

Authors:  A N Houghton; D Mintzer; C Cordon-Cardo; S Welt; B Fliegel; S Vadhan; E Carswell; M R Melamed; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

View more
  11 in total

1.  IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.

Authors:  Barbara Dillinger; Sarah Ahmadi-Erber; Manuel Lau; Markus A Hoelzl; Friedrich Erhart; Birgit Juergens; Dietmar Fuchs; Andreas Heitger; Stephan Ladisch; Alexander M Dohnal
Journal:  Cell Immunol       Date:  2018-02-02       Impact factor: 4.868

2.  Overexpression of ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits glioma growth in vivo.

Authors:  Roger A Kroes; Huan He; Mark R Emmett; Carol L Nilsson; Franklin E Leach; I Jonathan Amster; Alan G Marshall; Joseph R Moskal
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

3.  Efflux of sphingolipids metabolically labeled with [1-3H]sphingosine, L-[3- 3H]serine and [9,10- 3H]palmitic acid from normal cells in culture.

Authors:  Vanna Chigorno; Mariateresa Sciannamblo; Joanna Mikulak; Alessandro Prinetti; Sandro Sonnino
Journal:  Glycoconj J       Date:  2006-05       Impact factor: 2.916

Review 4.  Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.

Authors:  Angelica Pace; Fabio Scirocchi; Chiara Napoletano; Ilaria Grazia Zizzari; Luca D'Angelo; Antonio Santoro; Marianna Nuti; Hassan Rahimi; Aurelia Rughetti
Journal:  Int J Mol Sci       Date:  2022-06-05       Impact factor: 6.208

5.  Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Authors:  Thomas N Seyfried; Purna Mukherjee
Journal:  J Oncol       Date:  2010-06-20       Impact factor: 4.375

6.  A rapid method for the preparation of ganglioside Glac2 (GD3).

Authors:  R Jennemann; H Wiegandt
Journal:  Lipids       Date:  1994-05       Impact factor: 1.880

Review 7.  Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma.

Authors:  Chaitanya Tondepu; Lohitash Karumbaiah
Journal:  Adv Healthc Mater       Date:  2021-12-29       Impact factor: 11.092

8.  GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.

Authors:  Barun Mahata; Soumika Biswas; Patricia Rayman; Ali Chahlavi; Jennifer Ko; Ashish Bhattacharjee; Yu-Teh Li; Yuntao Li; Tanya Das; Gaurisankar Sa; Baisakhi Raychaudhuri; Michael A Vogelbaum; Charles Tannenbaum; James H Finke; Kaushik Biswas
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

Review 9.  Ganglioside GD3 synthase (GD3S), a novel cancer drug target.

Authors:  Jinyi Liu; Xiangjin Zheng; Xiaocong Pang; Li Li; Jinhua Wang; Cui Yang; Guanhua Du
Journal:  Acta Pharm Sin B       Date:  2018-07-25       Impact factor: 11.413

Review 10.  The Role of NKT Cells in Glioblastoma.

Authors:  Emily E S Brettschneider; Masaki Terabe
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.